By Josh Beckerman 

The U.S. Food and Drug Administration said the potential Covid-19 vaccine from Pfizer Inc. and BioNTech SE will be discussed at a Dec. 10 meeting of the Vaccines and Related Biological Products Advisory Committee.

The FDA intends to make background materials available to the public no later than two business days before the meeting. The agency said it "recognizes that transparency and dialogue are critical for the public to have confidence in Covid-19 vaccines."

On Friday, the companies filed an application for an emergency use authorization.

The FDA said it "has been preparing for the review of EUAs for Covid-19 vaccines for several months and stands ready to do so as soon as an EUA request is submitted. While we cannot predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible, while still doing so in a thorough and science-based manner."

The agency plans to livestream the meeting on its YouTube, Facebook and Twitter channels.


Write to Josh Beckerman at


(END) Dow Jones Newswires

November 20, 2020 18:28 ET (23:28 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.